The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.

Multiple major M&A transactions are underway across various sectors. Papa John's received a $1.5 billion privatization proposal from Irth Capital Management backed by Brookfield Asset Management. Shell sold Jiffy Lube to Monomoy Capital Partners for $1.3 billion. Meta acquired AI social network Moltbook, while Google completed its $32 billion acquisition of cloud security platform Wiz. Other notable deals include Agilent acquiring Biocare Medical for $950 million and Universal Health Services acquiring Talkspace for $835 million. Meanwhile, several retailers including Eddie Bauer and Saks Global are closing stores amid bankruptcy proceedings.

The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.

Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million to strengthen its pathology and immunohistochemistry offerings. The deal is expected to close by Q4 fiscal 2026 and become accretive to EPS within 12 months. However, Agilent's stock has declined 5.60% over the past year and is currently trading below key moving averages, showing weak momentum despite the strategic acquisition.

The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.

The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.

The global automated sample preparation market is expected to expand at a 10.10% CAGR from 2025 to 2031, driven by pharmaceutical R&D investments, need for reproducibility, and AI/ML adoption. However, high initial costs and integration challenges with legacy systems remain significant barriers, particularly for smaller laboratories and SMEs.

The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.

The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology investments. Disease diagnostics account for 74.42% of revenue, with cancer diagnostics representing 60% of biopsy applications globally.

The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.

Agilent Technologies delivered strong Q4 FY2025 results with $1.86B revenue (9.4% reported growth, 7.2% core growth) and $1.59 non-GAAP EPS, marking the sixth consecutive quarter of sequential core growth acceleration. The company's diversified portfolio spanning chromatography, mass spectrometry, and lab automation, combined with its high-margin CrossLab services business, provides structural resilience during industry downturns. Trading at 23.7x EV/EBITDA with a modest P/E premium to historical averages, Agilent's valuation reflects strong execution, pricing power, and efficient capital allocation through buybacks and strategic acquisitions like BioVectra.

The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.